BM 201
Alternative Names: BM201Latest Information Update: 24 Jan 2017
At a glance
- Originator BioMarin Pharmaceutical
- Class Peptide hydrolases
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Burns
Most Recent Events
- 23 Jan 2017 Discontinued - Preclinical for Burns in USA (unspecified route)
- 31 Oct 2000 Suspended-Preclinical for Burns in USA (Unknown route)